Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)

Author： Latif Tahir   Wood Laura   Connell Cindy   Smith David C.   Vaughn David   Lebwohl David   Peereboom David  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.23, Iss.1, 2005-01, pp. : 79-84

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Satraplatin: BMS 182751, BMY 45594, JM 216

By Adis International Limited  

Drugs in R&D, Vol. 8, Iss. 2, 2007-01 ,pp. : 125-132

Adis International

Access to resources Recommend Favorite

Satraplatin: BMS 182751, BMY 45594, JM 216

By  

Drugs in R&D, Vol. 3, Iss. 1, 2002-01 ,pp. : 67-71

Adis International

Access to resources Recommend Favorite

Novel Biological Agents for the Treatment of Hormone-Refractory Prostate Cancer (HRPC)

By  

Current Medicinal Chemistry, Vol. 12, Iss. 3, 2005-02 ,pp. : 277-296

Bentham Science Publishers

Access to resources Recommend Favorite

Phase II Study of CI-958 in Patients with Hormone Refractory Prostate Carcinoma

By Philip Kuebler J.   Moore Timothy   Pritchard James   Kraut Eric  

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 181-184

Springer Publishing Company

Access to resources Recommend Favorite

Hormone-Refractory Prostate Cancer: Where are We Going?

By Giuseppe Di Lorenzo  

Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. : 1109-1124

Adis International

Access to resources Recommend Favorite